Three-Gene Immunohistochemical Panel Adds to Clinical Staging Algorithms to Predict Prognosis for Patients With Esophageal Adenocarcinoma

Purpose Esophageal adenocarcinoma (EAC) is a highly aggressive disease with poor long-term survival. Despite growing knowledge of its biology, no molecular biomarkers are currently used in routine clinical practice to determine prognosis or aid clinical decision making. Hence, this study set out to identify and validate a small, clinically applicable immunohistochemistry (IHC) panel for prognostication in patients with EAC. Patients and Methods We recently identified eight molecular prognostic biomarkers using two different genomic platforms. IHC scores of these biomarkers from a UK multicenter cohort (N = 374) were used in univariate Cox regression analysis to determine the smallest biomarker panel with the greatest prognostic power with potential therapeutic relevance. This new panel was validated in two independent cohorts of patients with EAC who had undergone curative esophagectomy from the United States and Europe (N = 666). Results Three of the eight previously identified prognostic molecular biomarkers (epidermal growth factor receptor [EGFR], tripartite motif-containing 44 [TRIM44], and sirtuin 2 [SIRT2]) had the strongest correlation with long-term survival in patients with EAC. Applying these three biomarkers as an IHC panel to the validation cohort segregated patients into two different prognostic groups (P < .01). Adjusting for known survival covariates, including clinical staging criteria, the IHC panel remained an independent predictor, with incremental adverse overall survival (OS) for each positive biomarker (hazard ratio, 1.20; 95% CI, 1.03 to 1.40 per biomarker; P = .02). Conclusion We identified and validated a clinically applicable IHC biomarker panel, consisting of EGFR, TRIM44, and SIRT2, that is independently associated with OS and provides additional prognostic information to current survival predictors such as stage.

Download Full-text

150: Short- and Long-Term Survival of Combined Heart-Kidney Transplants Performed in the United States

The Journal of Heart and Lung Transplantation ◽

10.1016/j.healun.2008.11.828 ◽

2009 ◽

Vol 28 (2) ◽

pp. S118 ◽

Cited By ~ 1

Author(s):

S. Lee ◽

J. Connett ◽

M. Colvin-Adams

Keyword(s):

United States ◽

The United States ◽

Kidney Transplants ◽

Term Survival ◽

Long Term Survival ◽

Short And Long Term

Download Full-text

Long-term Survival of Dialysis Patients With Bacterial Endocarditis Undergoing Valvular Replacement Surgery in the United States

Circulation ◽

10.1161/circulationaha.113.002365 ◽

2013 ◽

Vol 128 (4) ◽

pp. 344-351 ◽

Cited By ~ 33

Author(s):

Maxwell D. Leither ◽

Gautam R. Shroff ◽

Shu Ding ◽

David T. Gilbertson ◽

Charles A. Herzog

Keyword(s):

United States ◽

The United States ◽

Bacterial Endocarditis ◽

Dialysis Patients ◽

Term Survival ◽

Long Term Survival ◽

Replacement Surgery ◽

Valvular Replacement

Download Full-text

Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series

World Journal of Surgical Oncology ◽

10.1186/s12957-021-02238-x ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Claudio F. Feo ◽

Giulia Deiana ◽

Chiara Ninniri ◽

Giuseppe Cherchi ◽

Paola Crivelli ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Locally Advanced ◽

Operating Time ◽

Vascular Resection ◽

Ductal Adenocarcinoma ◽

Term Survival ◽

Aggressive Approach ◽

Long Term Survival ◽

Cox Regression Analysis

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis. Radical surgery is the best option for cure and, nowadays, it is performed by many surgeons also in cases of vascular infiltration. Whether this aggressive approach to a locally advanced PDAC produces a survival benefit is under debate. Most data in the literature come from retrospective comparative studies; therefore, it is still unclear if such an extensive surgery for an advanced cancer is justified. Methods A retrospective review of patients with PDAC treated at our institution over a 12-year period was performed. Data concerning patients’ characteristics, operative details, postoperative course, and long-term survival were retrieved from prospective databases and analysed. Factors associated with poor survival were assessed via Cox regression analysis. Results A total of 173 patients with PDAC were included in the analysis, 41 subjects underwent pancreatectomy with vascular resection for locally advanced disease, and in 132 patients, only a pancreatic resection was undertaken. Demographics, major comorbidities, and tumour characteristics were similar between the two groups. Length of surgery (P=0.0006), intraoperative blood transfusions (P<0.0001), and overall complications (P<0.0001) were significantly higher in the vascular resection group. Length of hospital stay (P=0.684) and 90-day mortality (P=0.575) were comparable between groups. Overall median survival (P= 0.717) and survival rates at 1, 3, and 5 years (P=0.964, P=0.500, and P=0.445, respectively) did not differ significantly between groups. Age ≥70 years and postoperative complications were independent predictors of lower survival. Conclusions Our study confirms that pancreatectomy with vascular resection for a locally advanced PDAC is a complex operation associated with a significant longer operating time that may increase morbidity; however, in selected patients, R0 margins can be obtained with an acceptable long-term survival rate. Older patients are less likely to benefit from surgery.

Download Full-text

Su1285 Long-Term Survival of Patients With Transplant-Eligible Hepatocellular Carcinoma (HCC) in Post-MELD Exception Era in the United States Between 2004 and 2007

Gastroenterology ◽

10.1016/s0016-5085(13)61652-2 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-447-S-448

Author(s):

Pardha Devaki ◽

Vidyasagargoud Marupakula ◽

Sharad Nangia ◽

Basile Njei ◽

Ivo C. Ditah ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

The United States ◽

Term Survival ◽

Long Term Survival

Download Full-text

PCN111 Incidence and Long-Term Survival of Cervical Cancer Patients in the United States, an Analysis of SEER Database

Value in Health ◽

10.1016/j.jval.2021.04.203 ◽

2021 ◽

Vol 24 ◽

pp. S40

Author(s):

M. Chaudhuri ◽

A. Hait ◽

S. Das ◽

N. Kathe

Keyword(s):

United States ◽

Cervical Cancer ◽

Cancer Patients ◽

The United States ◽

Seer Database ◽

Term Survival ◽

Long Term Survival

Download Full-text

Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma

Revista do Colégio Brasileiro de Cirurgiões ◽

10.1590/s0100-69912009000100007 ◽

2009 ◽

Vol 36 (1) ◽

pp. 24-34 ◽

Cited By ~ 10

Author(s):

Leandro Totti Cavazzola ◽

André Ricardo Pereira da Rosa ◽

Carlos Cauduro Schirmer ◽

Richard Ricachenevski Gurski ◽

João Pedro Bueno Telles ◽

...

Keyword(s):

Esophageal Adenocarcinoma ◽

Curative Resection ◽

P53 Protein ◽

Vascular Endothelial ◽

Clinicopathological Factors ◽

Term Survival ◽

Long Term Survival ◽

End Stage ◽

Endothelial Growth Factor

OBJECTIVES: To correlate the expression of p53 protein and VEGF with the prognosis of patients submitted to curative resection to treat esophageal adenocarcinoma. METHODS: Forty-six patients with esophageal adenocarcinoma, submitted to curative resection, were studied. The expressions of p53 protein and VEGF were assessed by immunohistochemistry in 52.2% and 47.8% of tumors, respectively. RESULTS: P53 protein and VEGF expressions coincided in 26% of the cases, and no correlation between these expressions was observed. None of the clinicopathological factors showed a significant correlation with p53 protein or VEGF expressions. There was no significant association between p53 protein and VEGF expressions and long-term survival. CONCLUSION: The expression of p53 protein and VEGF did not correlate with prognosis in esophageal adenocarcinoma patients submitted to curative resection.

Download Full-text